Abstract 25P
Background
With the advent of novel antibody-drug conjugate (ADC), an emerging subgroup of human epidermal growth factor receptor 2 (HER2)-low breast cancer has been recognized which may take advantage from the anti-tumor activity. We took advantage of Taiwan Cancer Registry (TCR) to evaluate the clinical presentations and prognostication for HER2-low breast cancer.
Methods
HER2-low breast cancers were defined operationally with HER2 immunohistochemistry (IHC) 1+ or 2+ with a negative fluorescence in situ hybridization (FISH) while HER2-zero defined with an IHC score 0. Breast cancer index cases (n=189465) from TCR between 2007 and 2017 were reduced to 133546 sides of breast cancer per subject. Clinical features such as IHC test, stage, grade and outcomes such as relapse-free and overall survival were compared between HER2-low and HER2-zero.
Results
The safety analysis group comprised 37195 HER2-negative breast cancers, including 14288 IHC 1+, 10486 FISH-negative, 8907 IHC 0 and 3323 IHC 2+/FISH-undetermined cases. Among HER2-negative breast cancers, the proportion of HER2-low and HER2-zero was 68.9% and 31.1%, respectively, after excluding HER2 ambiguity. Overall survival was 95.7% versus 95.9% for HER2-low and HER2-zero breast cancers, which was 94.1% and 94.7% for relapse-free survival. The distributions of pathological stages from 0 to IV were 6.7%, 41.5%, 38.5%, 13.1% and 0.3% for HER2-low and were 8.5%, 42.8%, 37.5%, 11% and 0.4% for HER2-zero breast cancers. Regarding estrogen receptor (ER) and progesterone receptor (PR) status, 87.6% and 80.9% of the HER2-low cases were ER+ and PR+ while 81.9% and 74.8% of the HER2-zero patients were ER+ and PR+. High or poorly differentiated grade was reported from 23.4% of HER2-low and 25.5% of HER2-zero breast cancers. The diagnosed age was 54 versus 54.3 between HER2-low and HER2-zero breast cancers (P=0.02).
Conclusions
HER2-low status is not a prognostic marker for Taiwanese breast cancers while a slightly younger age of disease onset, less than half diagnosed with stage 0 and I, more ER and PR positivity and fewer grade III disease were observed for HER2-low phenotype compared with HER2-zero counterpart. These trivial differences distinguished HER2-low from HER2-zero spectrum among Taiwanese HER2-negative breast cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
LMT.
Funding
Melissa Lee Cancer Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract